science wire

« BACK

Pharmacology



Results 401 - 450 of 1869.
« Previous 1 ... 5 6 7 8 9 10 11 12 13 ... 38 Next »


Chemistry - Pharmacology - 17.10.2019
Change of perspective
Change of perspective
Gerd Folkers was the first head of Critical Thinking ETH (CTETH) and left an indelible mark on the initiative.

Pharmacology - Innovation - 14.10.2019
A smart speaker helps care for the elderly at home
A smart speaker helps care for the elderly at home
Two students from EPFL have developed a smart speaker with voice-activation technology that connects patients directly to their loved ones as well as caregivers and emergency services.

Health - Pharmacology - 14.10.2019
Organs ’too risky’ to donate may be safer than we think
Detailed infectious virus testing shows potential for increasing organ donation in Australia, by including people previously ineligible due to increased risk of blood-borne viruses, writes Dr Karen Waller and Prof Angela Webster.

Pharmacology - Health - 14.10.2019
Roche’s MabThera/Rituxan (rituximab) superior to mycophenolate mofetil in patients with pemphigus vulgaris
40% of patients with pemphigus vulgaris (PV) achieved sustained complete remission, without the use of steroids for 16 weeks or more, when treated with MabThera/Rituxan compared to 9.5% of pat

Health - Pharmacology - 10.10.2019
Digital service launched to help oesophageal cancer patients
A new smart phone app and web portal to help oesophageal cancer patients and their carers understand and manage their journey better has been launched today by UCL, University College London Hospital (UCLH) and digital health company, Living With.

Pharmacology - Health - 09.10.2019
Sixth patient receives pioneering treatment for CJD
A sixth patient is receiving a new drug for Creutzfeldt-Jakob disease (CJD) developed by researchers at the Medical Research Council (MRC) Prion Unit at UCL.

Pharmacology - Health - 08.10.2019
Novartis receives FDA approval for Beovu , offering wet AMD patients vision gains and greater fluid reductions vs aflibercept
In two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of patients

Pharmacology - 07.10.2019
New capsule can orally deliver drugs that usually have to be injected
New capsule can orally deliver drugs that usually have to be injected
Coated pill carries microneedles that deliver insulin and other drugs to the lining of the small intestine.

Pharmacology - Life Sciences - 05.10.2019
AveXis presents updated STRONG data at WMS demonstrating a higher mean increase in Hammersmith Functional Motor Scale-Expanded (HFMSE) scores among older SMA Type 2 patients following one-time intrathecal administration of AVXS-101
Older patients (= 2 years and < 5 years) achieved a mean increase of 5.9 points from baseline in HFMSE scores, nearly double the clinically meaningful threshold (at a mean duration of follo

Health - Pharmacology - 03.10.2019
New partnership aims to identify new disease mechanisms and potential targets for treatment of non-alcoholic fatty liver disease
A new partnership between scientists at the University of Birmingham and global healthcare company Novo Nordisk aims to discover new treatments for people suffering from fatty liver disease.

Life Sciences - Pharmacology - 03.10.2019
Bringing neuroscience to bear on addiction policy
Bringing neuroscience to bear on addiction policy
Keith Humphreys founded the Stanford Network on Addiction Policy to help bring more science to debates over drug policy.

Health - Pharmacology - 02.10.2019
Immune cells in the spotlight
Immune cells in the spotlight
How do immune cells behave in the body? What happens during immunotherapy, which is designed to encourage the body's own immune system to attack a disease? To answer these questions, the European Union (EU) brings together leading experts from research and the pharmaceutical industry.

Pharmacology - Health - 02.10.2019
Novartis positive 52-week PREVENT data confirm Cosentyx efficacy in addressing entire axSpA spectrum
Phase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)   Novartis plans FDA submission for nr-axSpA, having submitted to EMA previously.

Pharmacology - Health - 01.10.2019
Novartis and Microsoft announce collaboration to transform medicine with artificial intelligence
Multiyear alliance underpins the Novartis commitment to leverage data & Artificial Intelligence (AI) to transform how medicines are discovered, developed and commercialized Novartis to establish

Pharmacology - Health - 30.09.2019
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer
Roche presents positive Phase III results for Tecentriq (atezolizumab) in combination with platinum-based chemotherapy in people with previously untreated advanced bladder cancer IMvigor130 is the fi

Pharmacology - Health - 30.09.2019
Novartis announces positive results from Phase III PALLADIUM study of inhaled combination QMF149 in patients with uncontrolled asthma
Once-daily QMF149 demonstrated superior improvement in lung function versus mometasone furoate, meeting primary endpoint PALLADIUM is part of Phase III PLATINUM clinical development program, which ev

Pharmacology - Health - 30.09.2019
Novartis announces positive results from Phase III IRIDIUM study of inhaled combination QVM149 in patients with uncontrolled asthma
Once-daily QVM149 demonstrated statistically significant improvement in lung function versus QMF149, meeting primary endpoint ,   IRIDIUM is largest study in Phase III PLATINUM clinical development p

Pharmacology - Health - 30.09.2019
FDA approves Roche’s Rituxan (rituximab) in children with two rare blood vessel disorders
Rituxan is the first and only FDA-approved treatment for paediatric patients 2 years of age and older living with granulomatosis with polyangiitis or microscopic polyangiitis These two forms of vascu

Pharmacology - Health - 29.09.2019

Pharmacology - Health - 28.09.2019
Roche to present new and updated data at ESMO 2019 reinforcing the use of Alecensa in the first-line setting for advanced ALK-positive non-small cell lung cancer
New real-world data from the Flatiron database supports clinical benefits of Alecensa (alectinib) across time to treatment discontinuation, real-world progression free survival and overall survival F

Pharmacology - Health - 27.09.2019
Roche’s Tecentriq improves overall survival as a first-line monotherapy in certain people with advanced non-small cell lung cancer
Phase III IMpower110 study showed Tecentriq monotherapy helped people with advanced non-small cell lung cancer (NSCLC) with high PD-L1 expression live longer compared with chemotherapy alone Data wil

Pharmacology - Health - 27.09.2019
Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma
The study showed a confirmed objective response rate of 36% for people treated with the Tecentriq and Avastin combination in unresectable hepatocellular carcinoma who have not received prior systemic

Health - Pharmacology - 26.09.2019
UCLA to lead $25 million study of opioids in rural America
Scientists from the UCLA Integrated Substance Abuse Programs will lead a $25 million study on in rural America.

Health - Pharmacology - 26.09.2019
Spotlight on... Dr Jane Kinghorn
This week Jane, Director of the Translational Research Office (TRO), talks about developing solutions to unmet medical needs, and new support for Early Career Researchers.

Environment - Pharmacology - 25.09.2019

Life Sciences - Pharmacology - 23.09.2019
How we are tackling dementia and stigma
A language app to improve diagnosis and peer-support dementia coaching are some of the Sydney projects aiming to tackle the obstacles and stigma surrounding dementia.

Pharmacology - Health - 23.09.2019
Roche to present new data from its broad oncology portfolio at the European Society for Medical Oncology 2019 Congress
First positive results from a Phase III cancer immunotherapy combination study in people with previously untreated advanced bladder cancer First results from the BFAST study testing Foundation Medici

Health - Pharmacology - 20.09.2019
FDA approves cobas Babesia, Roche’s first whole blood test for donor screening
Roche is dedicated to helping save patients' lives by delivering state-of-the-art solutions to aid in the protection of the global blood supply from infectious diseases If undetected, Babesia infecti

Pharmacology - Health - 19.09.2019
AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1
New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age-appropriate major milestone gain Updated results from global STR1

Pharmacology - Health - 18.09.2019
FDA grants Breakthrough Therapy Designation for Roche’s Gazyva (obinutuzumab) in Lupus Nephritis
There are currently no U.S. FDA-approved medicines for lupus nephritis The designation is based on the results of the phase II NOBILITY study that showed Gazyva, in combination with sta

Pharmacology - Health - 17.09.2019
Novartis Cosentyx positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis
Phase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA).

Pharmacology - Health - 13.09.2019
Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis
Both ASCLEPIOS I and II studies met their primary endpoints in patients with relapsing forms of MS (RMS) ; overall ofatumumab (OMB157), a subcutaneous, potent, fully-human antibody targeting CD20 pos

Pharmacology - Health - 13.09.2019
Roche presents new 6-year OCREVUS (ocrelizumab) data which showed that earlier initiation and continuation of treatment reduced disability progression in multiple sclerosis
Post-hoc analysis from a Phase III open-label extension study showed a 42 percent reduction in the risk of PPMS patients needing a wheelchair after 6.5 years of OCREVUS treatment compared with patients who started OCREVUS after the double-blind period Interim analysis of Phase IIIb study shows 87 percent of patients with suboptimal response to previous treatment had no evidence of disease activity one year after switching to OCREVUS Separ

Pharmacology - Health - 13.09.2019
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin showed non-inferiority when compared to intravenous formulations for people with HER2-positive breast cancer
New fixed-dose combination is administered under the skin in just minutes, significantly reducing the time spent receiving treatment Data will be submitted to health authorities around the world, inc

Health - Pharmacology - 12.09.2019
Pioneering data research centres to enable cutting-edge research and innovation to benefit UK patients
The University of Birmingham will play a key role in new data hubs that will enable cutting-edge research for health discoveries and aim to give patients across the UK faster access to pioneering new treatments. Led by Health Data Research UK , the hubs aim to improve the lives of people with debilitating conditions, and will link up different types of health data and make it more easily accessible and user-friendly for research, while maintaining strict controls around data privacy and consent.

Pharmacology - Health - 12.09.2019
Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum
Pivotal phase III SAkuraStar study shows 55% reduction in the risk of relapse for satralizumab monotherapy versus placebo presented at ECTRIMS congress 2019 74% reduction in the risk of relapse for s

Pharmacology - Health - 12.09.2019
Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy
Data will be shared with health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) Roche today announced positive data from the Phase III IM
« Previous 1 ... 5 6 7 8 9 10 11 12 13 ... 38 Next »

This site uses cookies and analysis tools to improve the usability of the site. More information. |